

Big Data Studies and Small Data Pharmacogenomic Studies

Course Syllabus

2024-2025

ONLINE COURSE

MODULE 3

Pharmacogenomics

DATE/TIME

Thursday, Dec 5th, 2024
13:30 to 16:30 EST

LANGUAGE

English

FREE REGISTRATION

www.camccol.com

DESCRIPTION

This course will summarize value and limitations of Big and Small data drug outcome studies and why both study types improve the rigour of each other.

LEARNING OBJECTIVES

- Summarize the value and limitations of Big Data drug outcome studies
- Summarize the value and limitations of Small Data drug outcome studies
- Appraise the value of both study designs examining the same outcome

PRE-READINGS

Bissel M. Reproducibility: The risks of the replication drive. [10.1038/503333a](https://doi.org/10.1038/503333a)

Allison DB & Fineberg HV. EPA's proposed transparency rule: Factors to consider, many; planets to live on, one. [10.1073/pnas.1922721117](https://doi.org/10.1073/pnas.1922721117)



PRESENTED BY

Dr. Bruce Carleton

Professor, University of British Columbia

✉ bcarleton@popi.ubc.ca